Sign in

Trial result ·

Pain-Specific Benefits of Higher-Dose Neubotulinum Toxin Type A in Cervical Dystonia: A Multicenter Randomized Double-Blind Crossover Trial.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This trial tested a botulinum toxin drug called Neubotulinum toxin type A. It was given to 50 adults with cervical dystonia. This condition can cause abnormal head posture and pain. Each person got both a 100 U dose and a 50 U dose. The order of the doses was chosen by chance. Each dose period lasted 12 weeks. Neither people nor staff knew which dose was given.

What they found

Overall scores for neck problem severity and disability did not differ between doses. Pain scores improved more with the 100 U dose. This pain result held up in a second way of checking. Social and emotional functioning also improved more with 100 U. The team checked 24 results together to limit chance findings. Only the pain and social-emotional results stayed clear after this check. No serious harmful events happened.

What it means for patients

The higher dose did not improve overall cervical dystonia severity. But it was linked to more pain relief. It was also linked to better social and emotional functioning. The higher dose seemed to be tolerated as well as the lower one.

Why it is not certain yet

The pain and social-emotional results were secondary findings. The main overall score showed no clear difference between doses. The authors say the findings need to be confirmed. Each dose was followed for 12 weeks. Results for longer use are not given in the abstract.

Source

Pain-Specific Benefits of Higher-Dose Neubotulinum Toxin Type A in Cervical Dystonia: A Multicenter Randomized Double-Blind Crossover Trial.

PubMed · PMID 42784294

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Dystonia publications